NASDAQ:LENZ LENZ Therapeutics (LENZ) Stock Price, News & Analysis $35.50 +1.18 (+3.44%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About LENZ Therapeutics Stock (NASDAQ:LENZ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LENZ Therapeutics alerts:Sign Up Key Stats Today's Range$33.85▼$36.0950-Day Range$20.91▼$37.2552-Week Range$14.42▼$38.93Volume88,014 shsAverage Volume160,089 shsMarket Capitalization$976.25 millionP/E RatioN/ADividend YieldN/APrice Target$35.40Consensus RatingBuy Company OverviewLENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Read More… Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. LENZ Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks12th Percentile Overall ScoreLENZ MarketRank™: LENZ Therapeutics scored higher than 12% of companies evaluated by MarketBeat, and ranked 902nd out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.6 / 5Analyst RatingBuy Consensus RatingLENZ Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLENZ Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about LENZ Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for LENZ Therapeutics are expected to decrease in the coming year, from ($2.09) to ($2.54) per share.Price to Book Value per Share RatioLENZ Therapeutics has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about LENZ Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.22% of the float of LENZ Therapeutics has been sold short.Short Interest Ratio / Days to CoverLENZ Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in LENZ Therapeutics has recently increased by 2.99%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLENZ Therapeutics does not currently pay a dividend.Dividend GrowthLENZ Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.22% of the float of LENZ Therapeutics has been sold short.Short Interest Ratio / Days to CoverLENZ Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in LENZ Therapeutics has recently increased by 2.99%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News SentimentN/A News SentimentLENZ Therapeutics has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for LENZ Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders38.40% of the stock of LENZ Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENZ Therapeutics' insider trading history. Receive LENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LENZ Stock News HeadlinesLENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024November 15, 2024 | investorplace.comHC Wainwright Expects Higher Earnings for LENZ TherapeuticsNovember 13, 2024 | americanbankingnews.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…November 23, 2024 | WealthPress (Ad)LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024November 12, 2024 | investorplace.comLENZ Therapeutics to Participate in Upcoming Investor ConferencesNovember 12, 2024 | globenewswire.comLENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024November 11, 2024 | investorplace.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comPatent Challenges Threaten Lenz Therapeutics’ Market Strategy and Financial StabilityNovember 8, 2024 | markets.businessinsider.comSee More Headlines LENZ Stock Analysis - Frequently Asked Questions How have LENZ shares performed this year? LENZ Therapeutics' stock was trading at $16.20 at the start of the year. Since then, LENZ stock has increased by 119.1% and is now trading at $35.50. View the best growth stocks for 2024 here. How were LENZ Therapeutics' earnings last quarter? LENZ Therapeutics, Inc. (NASDAQ:LENZ) issued its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.09. Who are LENZ Therapeutics' major shareholders? Top institutional shareholders of LENZ Therapeutics include Geode Capital Management LLC (1.23%), State Street Corp (1.05%), Parkman Healthcare Partners LLC (0.51%) and Charles Schwab Investment Management Inc. (0.45%). Insiders that own company stock include Ra Capital Management, LP and James W Mccollum. View institutional ownership trends. How do I buy shares of LENZ Therapeutics? Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of LENZ Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LENZ Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings11/06/2024Today11/23/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LENZ Previous SymbolNASDAQ:LENZ CUSIPN/A CIK1815776 Webwww.graphitebio.com Phone650-484-0886FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$35.40 High Stock Price Target$38.00 Low Stock Price Target$32.00 Potential Upside/Downside-0.3%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.48% Return on Assets-55.50% Debt Debt-to-Equity RatioN/A Current Ratio28.63 Quick Ratio28.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.83 per share Price / Book4.53Miscellaneous Outstanding Shares27,500,000Free Float16,941,000Market Cap$976.25 million OptionableN/A Beta0.36 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:LENZ) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.